User login
Allowed Publications
LayerRx Mapping ID
395
Slot System
Featured Buckets
Featured Buckets Admin
Medscape Lead Concept
5000033
Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer
Article Type
Changed
Display Headline
Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer
Lung cancer remains the single biggest cause of cancer-related mortality, responsible for nearly a quarter of all deaths.1 Although major breakthroughs in the treatment of the most common form – non-small-cell lung cancer (NSCLC) – have been heralded in the past decade, many challenges remain. Here, we discuss how attempts to address these challenges are the driving force behind a continuing paradigm shift in lung cancer treatment.
EGFR and ALK: a model of targeted drug development
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(7)
Topics
Page Number
260-267
Legacy Keywords
lung cancer, non-small-cell lung cancer, NSCLC, EGFR, ALK, crizotinib, epidermal growth factor receptor, anaplastic lymphoma kinase, gefitinib, nivolumab, pembrolizumab, ipilimumab
Sections
Article PDF
Article PDF
Lung cancer remains the single biggest cause of cancer-related mortality, responsible for nearly a quarter of all deaths.1 Although major breakthroughs in the treatment of the most common form – non-small-cell lung cancer (NSCLC) – have been heralded in the past decade, many challenges remain. Here, we discuss how attempts to address these challenges are the driving force behind a continuing paradigm shift in lung cancer treatment.
EGFR and ALK: a model of targeted drug development
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
Click on the PDF icon at the top of this introduction to read the full article.
Lung cancer remains the single biggest cause of cancer-related mortality, responsible for nearly a quarter of all deaths.1 Although major breakthroughs in the treatment of the most common form – non-small-cell lung cancer (NSCLC) – have been heralded in the past decade, many challenges remain. Here, we discuss how attempts to address these challenges are the driving force behind a continuing paradigm shift in lung cancer treatment.
EGFR and ALK: a model of targeted drug development
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(7)
Issue
The Journal of Community and Supportive Oncology - 13(7)
Page Number
260-267
Page Number
260-267
Topics
Article Type
Display Headline
Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer
Display Headline
Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer
Legacy Keywords
lung cancer, non-small-cell lung cancer, NSCLC, EGFR, ALK, crizotinib, epidermal growth factor receptor, anaplastic lymphoma kinase, gefitinib, nivolumab, pembrolizumab, ipilimumab
Legacy Keywords
lung cancer, non-small-cell lung cancer, NSCLC, EGFR, ALK, crizotinib, epidermal growth factor receptor, anaplastic lymphoma kinase, gefitinib, nivolumab, pembrolizumab, ipilimumab
Sections
Citation Override
JCSO 2015;13:260-267
Disallow All Ads
Alternative CME
Article PDF Media
ASCO 2015: from data and learning, to daily practice
Article Type
Changed
Display Headline
ASCO 2015: from data and learning, to daily practice
The 2015 annual meeting of the American Society for Clinical Oncology, themed “Illumination and innovation: transforming data into learning,” brought together more than 37,000 attendees in Chicago and featured numerous clinical advances that will improve the lives of our cancer patients. That said, to a first-timer, the gathering probably would have felt like an update on using the immune system to fight cancer, despite our more than 30 years of using such strategies. The science behind the development of these promising monoclonal antibodies is outstanding, and the impact will certainly be far reaching.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(7)
Page Number
235-236
Legacy Keywords
monoclonal antibodies, immunotherapy, nivolumab, ipilimumab, metastatic melanoma, PD-L1, programmed cell death ligand-1, docetaxel, advanced prostate cancer, nonsquamous lung cancer, head and neck cancer, HPV-positive, ado-trastuzumab, T-DM1, aspirin, colon cancer
Sections
Article PDF
Article PDF
The 2015 annual meeting of the American Society for Clinical Oncology, themed “Illumination and innovation: transforming data into learning,” brought together more than 37,000 attendees in Chicago and featured numerous clinical advances that will improve the lives of our cancer patients. That said, to a first-timer, the gathering probably would have felt like an update on using the immune system to fight cancer, despite our more than 30 years of using such strategies. The science behind the development of these promising monoclonal antibodies is outstanding, and the impact will certainly be far reaching.
Click on the PDF icon at the top of this introduction to read the full article.
The 2015 annual meeting of the American Society for Clinical Oncology, themed “Illumination and innovation: transforming data into learning,” brought together more than 37,000 attendees in Chicago and featured numerous clinical advances that will improve the lives of our cancer patients. That said, to a first-timer, the gathering probably would have felt like an update on using the immune system to fight cancer, despite our more than 30 years of using such strategies. The science behind the development of these promising monoclonal antibodies is outstanding, and the impact will certainly be far reaching.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(7)
Issue
The Journal of Community and Supportive Oncology - 13(7)
Page Number
235-236
Page Number
235-236
Article Type
Display Headline
ASCO 2015: from data and learning, to daily practice
Display Headline
ASCO 2015: from data and learning, to daily practice
Legacy Keywords
monoclonal antibodies, immunotherapy, nivolumab, ipilimumab, metastatic melanoma, PD-L1, programmed cell death ligand-1, docetaxel, advanced prostate cancer, nonsquamous lung cancer, head and neck cancer, HPV-positive, ado-trastuzumab, T-DM1, aspirin, colon cancer
Legacy Keywords
monoclonal antibodies, immunotherapy, nivolumab, ipilimumab, metastatic melanoma, PD-L1, programmed cell death ligand-1, docetaxel, advanced prostate cancer, nonsquamous lung cancer, head and neck cancer, HPV-positive, ado-trastuzumab, T-DM1, aspirin, colon cancer
Sections
Citation Override
JCSO 2015;13:235-236
Disallow All Ads
Alternative CME
Article PDF Media
Document
Immunotherapy moves into the breast cancer landscape
Article Type
Changed
Display Headline
Immunotherapy moves into the breast cancer landscape
At this year’s San Antonio Breast Cancer Symposium, investigators presented some encouraging findings for difficult-to-treat patient populations, but issues such as therapy side effects and fertility concerns in younger patients also highlighted the importance of looking closely at the risk-benefit relationship in delivering quality, personalized care to patients with breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(1)
Topics
Page Number
30-33
Legacy Keywords
breast cancer, immunotherapy, pembrolizumab, SOFT trial, ovarian supression, tamoxifen, fulvestrant
Sections
Article PDF
Article PDF
At this year’s San Antonio Breast Cancer Symposium, investigators presented some encouraging findings for difficult-to-treat patient populations, but issues such as therapy side effects and fertility concerns in younger patients also highlighted the importance of looking closely at the risk-benefit relationship in delivering quality, personalized care to patients with breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
At this year’s San Antonio Breast Cancer Symposium, investigators presented some encouraging findings for difficult-to-treat patient populations, but issues such as therapy side effects and fertility concerns in younger patients also highlighted the importance of looking closely at the risk-benefit relationship in delivering quality, personalized care to patients with breast cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(1)
Issue
The Journal of Community and Supportive Oncology - 13(1)
Page Number
30-33
Page Number
30-33
Topics
Article Type
Display Headline
Immunotherapy moves into the breast cancer landscape
Display Headline
Immunotherapy moves into the breast cancer landscape
Legacy Keywords
breast cancer, immunotherapy, pembrolizumab, SOFT trial, ovarian supression, tamoxifen, fulvestrant
Legacy Keywords
breast cancer, immunotherapy, pembrolizumab, SOFT trial, ovarian supression, tamoxifen, fulvestrant
Sections
Citation Override
JCSO 2015:13;30-33
Disallow All Ads
Alternative CME
Article PDF Media
Document